Current Edition


As biotech retreats, gene therapy companies retrench and redraw plans

Bluebird bio has spent the better part of two decades developing gene therapies for rare diseases. This summer, after years of clinical trials, setbacks and …

Continue Reading →

After slower-than-expected review, Pfizer and Arena close buyout deal

Dive Brief: Arena Pharmaceuticals’ $7 billion sale to Pfizer closed on Friday, ending a slightly protracted regulatory review that raised questions about whether the deal would …

Continue Reading →

Drug, device companies gave docs, hospitals $8.4B in 2017

Doctors and teaching hospitals received $8.4 billion from drug and device companies in 2017, according to the latest Centers for Medicare and Medicaid Services Open …

Continue Reading →

Biopharmaceuticals Market Strongly guided by Companies like ABBVIE, AMGEN, BRISTOL

The market is expected to register a CAGR of 8.5% during the forecast period 2018 to 2023. North America dominates the market due to the …

Continue Reading →